Omada Health is trading at $19.99, up 5.16% in pre-market on October 28, 2026, with no verified company-specific catalyst identified.
- Omada’s third-quarter results are scheduled for November 5, not October 28.
- On October 27, a Citizens analyst preview reiterated a $32 target and Market Outperform rating; available reporting does not establish that it drove the rise.
- Supplied broader index moves are mixed and modest, and do not clearly explain the increase.